Syneos Health SYNH recently entered into a definitive agreement to be acquired by a private investment consortium in an all-cash transaction of approximately $7.1 billion. The consortium of private ...

Syneos Health inked a multiyear deal with Microsoft to further develop a platform that leverages machine learning to support and speed the analysis, design and operations of clinical trials and ...

Syneos Health has officially gone private, the company announced Thursday morning. The 2023 MM+M Agency 100 honoree completed the $7.1 billion all-cash transaction with a cohort of private equity ...

Syneos Health cemented a multi-year deal to use Microsoft’s platform for deploying artificial intelligence (AI) in its clinical trials and commercial programs. The agreement announced this week ...

Syneos Health, Inc. SYNH is well-poised for growth in the coming quarters, backed by strategic partnership deals and contributions from the Syneos One portfolio. The company’s Clinical Solutions arm ...

Syneos Health, a leading biopharmaceutical contract research organization, agreed to be acquired for $7.1 billion by a group of private equity firms. Elliott Investment Management, Patient Square ...

All the rumors are true. After months of sale speculation, Syneos Health has officially been snapped up by three private investment firm affiliates for the eye-watering sum of $7.1 billion. The North ...

Syneos Health (NASDAQ:SYNH) is being acquired by a private equity consortium in a transaction valued at ~$7.1B, including outstanding debt. The consortium which consists of affiliates composed of ...

(Reuters) -Syneos Health Inc is making a new effort to sell itself after a reduced backlog of contracts for providing clinical research to drug developers led to a 52% plunge in its shares over the ...

Syneos Health Inc.’s stock SYNH soared 9% in premarket trade Wednesday, after the biopharma services company said it has agreed to be acquired by a private investment consortium for about $7.1 billion ...

March 9 (Reuters) - Syneos Health Inc SYNH.O, a U.S. contract research organization (CRO) that serves the pharmaceutical industry, is exploring a sale, people familiar with the matter said on Monday.